Peptide Comparison
VIP vs Oxytocin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Oxytocin has stronger documented evidence (FDA-Approved) than VIP (Phase 3 (Aviptadil) / Off-Label) while both occupy the neuropeptide class. When clinical-evidence tier is the deciding factor, Oxytocin is the safer pick. VIP may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: hypotension. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| VIP | Oxytocin | |
|---|---|---|
| Class | Neuropeptide hormone; multi-organ regulator | Posterior pituitary hormone |
| Drug class | Other & Emerging | Sexual-Health |
| Mechanism | VPAC1/VPAC2 receptor agonist; vasodilation; anti-inflammatory; surfactant production | OXT receptor agonist; uterine contraction; social bonding and stress regulation pathways |
| Route | Intranasal / IV / SC | IV / IM / Intranasal / SC |
| Half-life | ~1-2 min (IV) | ~3-5 min (IV) |
| Dosage (research) | Intranasal 50-100 mcg 4x daily (off-label); IV in COVID trials | 10 IU intranasal daily for bonding off-label (Heinrichs et al. paradigm starting dose, max 40 IU/day in research trials); 10 IU IM post-partum (FDA Pitocin label dose for uterine atony) |
| Evidence tier | Phase 3 (Aviptadil) / Off-Label | FDA-Approved |
| Research depth | 161 indexed | 332 indexed |
| Availability | Investigational / Compounded | Prescription |
| Reported risks | Hypotension; flushing; diarrhea | Hyponatremia with high doses; hypotension; allergic reactions |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick VIP or Oxytocin?
Oxytocin has stronger documented evidence (FDA-Approved) than VIP (Phase 3 (Aviptadil) / Off-Label) while both occupy the neuropeptide class. When clinical-evidence tier is the deciding factor, Oxytocin is the safer pick. VIP may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between VIP and Oxytocin?
VIP is classed as Neuropeptide hormone; multi-organ regulator; Oxytocin is classed as Posterior pituitary hormone. Reported mechanism: VIP, VPAC1/VPAC2 receptor agonist; vasodilation; anti-inflammatory; surfactant production; Oxytocin, OXT receptor agonist; uterine contraction; social bonding and stress regulation pathways. Reported half-life: VIP, ~1-2 min (IV); Oxytocin, ~3-5 min (IV). Routes in published studies: VIP, Intranasal / IV / SC; Oxytocin, IV / IM / Intranasal / SC.
Which has stronger evidence, VIP or Oxytocin?
Oxytocin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. VIP is graded Phase 3 (Aviptadil) / Off-Label, with 19 cited sources on its reference page and 161 indexed studies. Oxytocin is graded FDA-Approved, with 73 cited sources on its reference page and 332 indexed studies.
Which is more accessible, VIP or Oxytocin?
Oxytocin is FDA-approved and VIP is not. Catalog status: VIP, Investigational / Compounded; Oxytocin, Prescription.
Are VIP and Oxytocin ever combined?
VIP and Oxytocin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…